Estelle Colin et al.
OMIXCARE: OMICS technologies solved about 33% of the patients with heterogeneous rare neuro-developmental disorders and negative exome sequencing results and identified 13% additional candidate variants
Frontiers in Cell and Developmental Biology 2022, vol. 10
doi: 10.3389/fcell.2022.1021785
![Logo France Génomique](https://www.france-genomique.org/wp-content/uploads/2019/03/logo-FG-blue-RVB-medium.png)